Numerical model of full-cardiac cycle hemodynamics in a total artificial heart and the effect of its size on platelet activation.

Abstract

The SynCardia total artificial heart (TAH) is the only Food and Drug Administration (FDA) approved device for replacing hearts in patients with congestive heart failure. It pumps blood via pneumatically driven diaphragms and controls the flow with mechanical valves. While it has been successfully implanted in more than 1300 patients, its size precludes implantation in smaller patients. This study's aim was to evaluate the viability of scaled-down TAHs by quantifying thrombogenic potentials from flow patterns. Simulations of systole were first conducted with stationary valves, followed by an advanced full-cardiac cycle model with moving valves. All the models included deforming diaphragms and platelet suspension in the blood flow. Flow stress accumulations were computed for the platelet trajectories and thrombogenic potentials were assessed. The simulations successfully captured complex flow patterns during various phases of the cardiac cycle. Increased stress accumulations, but within the safety margin of acceptable thrombogenicity, were found in smaller TAHs, indicating that they are clinically viable.

• Authors: Gil Marom, Wei-Che Chiu, Jessica R Crosby, Katrina J DeCook, Saurabh Prabhakar, Marc Horner, Marvin J Slepian, Danny Bluestein
• Journal: Journal of cardiovascular translational research (J Cardiovasc Transl Res) Vol. 7 Issue 9 Pg. 788-96 (Dec 2014) ISSN: 1937-5395 [Electronic] United States
• PMID: 25354999 (Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural)

Topics

• Equipment Design
• Heart, Artificial (adverse effects)
• Hemodynamics (physiology)
• Hydrodynamics
• Models, Biological
• Platelet Activation (physiology)
• Stress, Mechanical
• Thrombosis (etiology)